Supplemental Figure S5 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Jing Zhang; Sun Min Lim; Mi Ra Yu; Cheng Chen; Jia Wang; Wenqian Wang; Haopeng Rui; Jingtao Lu; Shun Lü; Tony Mok; Zhi Jian Chen; Byoung Chul Cho

doi:10.1158/2159-8290.26935016.v1

September 4, 2024

Supplemental Figure S5 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

View at Publisher

Ask AI

Bookmark

Share

Key Points

Supplemental in vivo assessments show that D3S-001 exhibits potent anti-tumor efficacy, overcoming nucleotide cycling barriers observed in prior KRAS G12C inhibitor therapies.
Analysis of preclinical models provides additional tolerability and safety data for D3S-001, showing sustained target engagement kinetics across evaluated treatment cohorts.
Findings highlight the robust preclinical activity of D3S-001 as a KRAS G12C inhibitor, though further validation in broader in vivo models remains warranted in future work.

Implication

Preclinical evaluation demonstrates in vivo efficacy and tolerability in animal models, indicating therapeutic potential of KRAS G12C inhibitor D3S-001.

Abstract

Supplemental Figure S5 shows D3S-001 additional in vivo efficacy and tolerability data.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e5968ab6db64358753122c https://doi.org/10.1158/2159-8290.26935016.v1

View at Publisher

Ask AI

Bookmark

Share

Supplemental Figure S5 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplemental Figure S5 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers